MedPath
HSA Product

NEVODIO TABLET 5MG

Product approved by Health Sciences Authority (SG)

Basic Information

NEVODIO TABLET 5MG

TABLET

Regulatory Information

SIN16446P

March 18, 2022

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XC07AB12

Company Information

PT. Dexa Medica

GLORIOUS DEXA SINGAPORE PTE. LTD.

GLORIOUS DEXA SINGAPORE PTE. LTD.

Active Ingredients

Detailed Information

Contraindications

**Contraindications:** - Hypersensitivity to the active substance or to any of the excipients. - Liver insufficiency or liver function impairment. - Pregnancy and lactation. - Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring i.v. inotropic therapy. In addition, as with other beta-blocking agents, nebivolol is contraindicated in: - Sick sinus syndrome, including sinoatrial block. - Second and third degree heart block (without a pacemaker). - History of bronchospasm and bronchial asthma. - Untreated pheochromocytoma. - Metabolic acidosis. - Bradycardia (heart <60 bpm prior to start therapy). - Hypotension (systolic blood pressure <90 mmHg). - Severe peripheral circulatory disturbances.

Indication Information

**Indications:** Hypertension Treatment of essential hypertension. Chronic heart failure (CHF) Treatment of stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients ≥70 years.

© Copyright 2025. All Rights Reserved by MedPath